CRANFORD, N.J., June 26,
2023 /PRNewswire/ -- Citius Pharmaceuticals,
Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage
biopharmaceutical company developing and commercializing
first-in-class critical care products, today announced that
it is set to be added to the broad-market Russell 3000®
Index and the small-cap Russell 2000® Index at the
conclusion of the annual reconstitution of Russell US Indexes,
effective at the opening of the U.S. equity markets on June 26, 2023.
"We are pleased to be included, once again, in the Russell U.S.
Equity Indexes and welcome the enhanced visibility this brings to
our diversified late-stage pipeline," stated Leonard Mazur, Chairman and CEO of Citius.
FTSE Russell determines membership for its Russell indexes
primarily by objective, market-capitalization rankings and style
attributes. Membership in the small-cap Russell 2000®
Index, which remains in place for one year, is based on membership
in the broad-market Russell 3000® Index. Citius
stock will also be automatically added to the appropriate growth
and value indexes.
FTSE Russell index expertise and products are used by
institutional and retail investors globally and roughly
$20.1 trillion is currently
benchmarked to its indexes, including approximately $12.1 trillion benchmarked to the Russell US
Equity Indexes. For more information on the Russell
2000® Index and the Russell indexes reconstitution,
visit the FTSE Russell website.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to
the development and commercialization of first-in-class critical
care products, with a focus on oncology, anti-infectives in adjunct
cancer care, unique prescription products, and stem cell therapies.
The Company's diversified pipeline includes two late-stage product
candidates, Mino-Lok®, an antibiotic lock solution for the
treatment of patients with catheter-related bloodstream infections,
which is currently enrolling patients in a Phase 3 Pivotal
superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy
for an initial indication in CTCL, for which a BLA is under review
by the FDA. Mino-Lok® was granted Fast Track designation by
the FDA. I/ONTAK has received orphan drug designation by the FDA
for the treatment of CTCL and PTCL. At the end of March 2023, Citius completed enrollment in its
Phase 2b trial of CITI-002, a topical
formulation for the relief of hemorrhoids. For more information,
please visit www.citiuspharma.com.
Safe Harbor
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
are made based on our expectations and beliefs concerning future
events impacting Citius. You can identify these statements by the
fact that they use words such as "will," "anticipate," "estimate,"
"expect," "plan," "should," and "may" and other words and terms of
similar meaning or use of future dates. Forward-looking statements
are based on management's current expectations and are subject to
risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from
those currently anticipated are: risks relating to the results of
research and development activities, including those from existing
and new pipeline assets, including Mino-Lok; our ability to
commercialize our products if approved by the FDA; our dependence
on third-party suppliers; our ability to procure cGMP
commercial-scale supply; the estimated markets for our product
candidates and the acceptance thereof by any market; the ability of
our product candidates to impact the quality of life of our target
patient populations; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships;
uncertainties relating to preclinical and clinical testing; the
early stage of products under development; our need for substantial
additional funds; market and other conditions; our ability to
attract, integrate, and retain key personnel; risks related to our
growth strategy; patent and intellectual property matters; our
ability to identify, acquire, close and integrate product
candidates and companies successfully and on a timely basis;
government regulation; competition; as well as other risks
described in our SEC filings. These risks have been and may be
further impacted by Covid-19 and could be impacted by any future
public health risks. Accordingly, these forward-looking statements
do not constitute guarantees of future performance, and you are
cautioned not to place undue reliance on these forward-looking
statements. Risks regarding our business are described in detail in
our Securities and Exchange Commission ("SEC") filings which are
available on the SEC's website at www.sec.gov, including in our
Annual Report on Form 10-K for the year ended September 30, 2022, filed with the SEC on
December 22, 2022, and updated by our
subsequent filings with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date hereof,
and we expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
Investor Contact:
Ilanit
Allen
ir@citiuspharma.com
908-967-6677 x113
Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-be-added-to-russell-3000-and-russell-2000-indexes-301862493.html
SOURCE Citius Pharmaceuticals, Inc.